TherapeuticsMD (TXMD) Competitors

Century Therapeutics (NASDAQ:IPSC) and TherapeuticsMD (NASDAQ:TXMD) are both small-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their institutional ownership, dividends, analyst recommendations, profitability, risk, media sentiment, earnings and valuation.

Do analysts prefer IPSC or TXMD?

Century Therapeutics presently has a consensus target price of $4.20, indicating a potential upside of 641.66%. Given Century Therapeutics' stronger consensus rating and higher possible upside, research analysts plainly believe Century Therapeutics is more favorable than TherapeuticsMD.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Century Therapeutics	0 Sell rating(s)	0 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	3.00
TherapeuticsMD	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

Does the media refer more to IPSC or TXMD?

In the previous week, Century Therapeutics had 2 more articles in the media than TherapeuticsMD. MarketBeat recorded 3 mentions for Century Therapeutics and 1 mentions for TherapeuticsMD. Century Therapeutics' average media sentiment score of 0.00 equaled TherapeuticsMD'saverage media sentiment score.

Company	Overall Sentiment
Century Therapeutics	Neutral
TherapeuticsMD	Neutral

Do insiders & institutionals believe in IPSC or TXMD?

50.2% of Century Therapeutics shares are owned by institutional investors. Comparatively, 30.7% of TherapeuticsMD shares are owned by institutional investors. 5.0% of Century Therapeutics shares are owned by insiders. Comparatively, 2.3% of TherapeuticsMD shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Which has stronger valuation & earnings, IPSC or TXMD?

TherapeuticsMD has lower revenue, but higher earnings than Century Therapeutics.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Century Therapeutics	$6.59M	7.40	-$126.57M	-$0.29	-1.95
TherapeuticsMD	$1.76M	7.80	-$2.18M	N/A	N/A

Which has more risk & volatility, IPSC or TXMD?

Century Therapeutics has a beta of 1.77, meaning that its stock price is 77% more volatile than the S&P 500. Comparatively, TherapeuticsMD has a beta of 0.65, meaning that its stock price is 35% less volatile than the S&P 500.

Is IPSC or TXMD more profitable?

Century Therapeutics has a net margin of -19.10% compared to TherapeuticsMD's net margin of -114.07%. TherapeuticsMD's return on equity of -7.86% beat Century Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Century Therapeutics	-19.10%	-10.71%	-5.96%
TherapeuticsMD	-114.07%	-7.86%	-5.46%

Summary

Century Therapeutics beats TherapeuticsMD on 9 of the 13 factors compared between the two stocks.